Friedrich Koehler1, Kerstin Koehler1, Oliver Deckwart1, Sandra Prescher1, Karl Wegscheider2, Sebastian Winkler3, Eik Vettorazzi2, Andreas Polze4, Karl Stangl5, Oliver Hartmann6, Almuth Marx7, Petra Neuhaus8, Michael Scherf9, Bridget-Anne Kirwan10, Stefan D Anker11. 1. Charité - Universitätsmedizin Berlin, Centre for Cardiovascular Telemedicine, Department of Cardiology and Angiology Campus Mitte, Berlin, Germany. 2. Institute of Medical Biometry and Epidemiology, University Medical Center Eppendorf, Hamburg, Germany. 3. Unfallkrankenhaus Berlin, Clinic for Internal Medicine, Berlin, Germany. 4. Hasso Plattner Institute gGmbH, Digital Engineering Faculty, University Potsdam, Potsdam, Germany. 5. Charité - Universitätsmedizin Berlin, Department of Cardiology and Angiology Campus Mitte, Berlin, Germany. 6. Frankfurt am Main, Germany. 7. Nuremberg, Germany. 8. University of Leipzig, Faculty of Medicine, Clinical Trial Centre Leipzig - KKS, Leipzig, Germany. 9. GETEMED Medizin- und Informationstechnik AG, Teltow, Germany. 10. London School of Hygiene and Tropical Medicine, Faculty of Epidemiology and Public Health, London, UK. 11. Department of Cardiology (CVK); and Berlin- Brandenburg Center for Regenerative Therapies (BCRT); German Centre for Cardiovascular Research (DZHK) partner site Berlin; Charité - Universitätsmedizin Berlin, Germany.
Abstract
BACKGROUND: Heart failure (HF) is a complex, chronic condition that is associated with debilitating symptoms, all of which necessitate close follow-up by health care providers. Lack of disease monitoring may result in increased mortality and more frequent hospital readmissions for decompensated HF. Remote patient management (RPM) in this patient population may help to detect early signs and symptoms of cardiac decompensation, thus enabling a prompt initiation of the appropriate treatment and care before a manifestation of HF decompensation. OBJECTIVE: The objective of the present article is to describe the design of a new trial investigating the impact of RPM on unplanned cardiovascular hospitalisations and mortality in HF patients. METHODS: The TIM-HF2 trial is designed as a prospective, randomised, controlled, parallel group, open (with randomisation concealment), multicentre trial with pragmatic elements introduced for data collection. Eligible patients with HF are randomised (1:1) to either RPM + usual care or to usual care only and are followed for 12 months. The primary outcome is the percentage of days lost due to unplanned cardiovascular hospitalisations or all-cause death. The main secondary outcomes are all-cause and cardiovascular mortality. CONCLUSION: The TIM-HF2 trial will provide important prospective data on the potential beneficial effect of telemedical monitoring and RPM on unplanned cardiovascular hospitalisations and mortality in HF patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT01878630.
RCT Entities:
BACKGROUND:Heart failure (HF) is a complex, chronic condition that is associated with debilitating symptoms, all of which necessitate close follow-up by health care providers. Lack of disease monitoring may result in increased mortality and more frequent hospital readmissions for decompensated HF. Remote patient management (RPM) in this patient population may help to detect early signs and symptoms of cardiac decompensation, thus enabling a prompt initiation of the appropriate treatment and care before a manifestation of HF decompensation. OBJECTIVE: The objective of the present article is to describe the design of a new trial investigating the impact of RPM on unplanned cardiovascular hospitalisations and mortality in HF patients. METHODS: The TIM-HF2 trial is designed as a prospective, randomised, controlled, parallel group, open (with randomisation concealment), multicentre trial with pragmatic elements introduced for data collection. Eligible patients with HF are randomised (1:1) to either RPM + usual care or to usual care only and are followed for 12 months. The primary outcome is the percentage of days lost due to unplanned cardiovascular hospitalisations or all-cause death. The main secondary outcomes are all-cause and cardiovascular mortality. CONCLUSION: The TIM-HF2 trial will provide important prospective data on the potential beneficial effect of telemedical monitoring and RPM on unplanned cardiovascular hospitalisations and mortality in HF patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT01878630.
Authors: Jacob Abraham; Rupinder Bharmi; Orvar Jonsson; Guilherme H Oliveira; Andre Artis; Ali Valika; Robert Capodilupo; Philip B Adamson; Gregory Roberts; Nirav Dalal; Akshay S Desai; Raymond L Benza Journal: JAMA Cardiol Date: 2019-06-01 Impact factor: 14.676
Authors: Serdar Tütüncü; Marcus Honold; Kerstin Koehler; Oliver Deckwart; Friedrich Koehler; Karl Georg Haeusler Journal: ESC Heart Fail Date: 2020-03-12
Authors: A Faragli; D Abawi; C Quinn; M Cvetkovic; T Schlabs; E Tahirovic; H-D Düngen; B Pieske; S Kelle; F Edelmann; Alessio Alogna Journal: Heart Fail Rev Date: 2021-09 Impact factor: 4.214